EQRx, Inc.

NasdaqGM:EQRX 株式レポート

時価総額:US$1.1b

EQRx 過去の業績

過去 基準チェック /06

EQRx's earnings have been declining at an average annual rate of -12.3%, while the Biotechs industry saw earnings growing at 17.4% annually.

主要情報

-12.3%

収益成長率

98.2%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率n/a
株主資本利益率-22.2%
ネット・マージンn/a
前回の決算情報30 Sep 2023

最近の業績更新

更新なし

Recent updates

We're Hopeful That EQRx (NASDAQ:EQRX) Will Use Its Cash Wisely

Jul 25
We're Hopeful That EQRx (NASDAQ:EQRX) Will Use Its Cash Wisely

EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans

Feb 22
EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About EQRx's (NASDAQ:EQRX) Cash Burn Rate

Nov 08
We're Not Very Worried About EQRx's (NASDAQ:EQRX) Cash Burn Rate

EQRx: Saving American Lives, Made Possible By Low Cost Chinese Drugs

Aug 28

 EQRx GAAP EPS of -$0.17 beats by $0.03

Aug 11

Here's Why We're Not Too Worried About EQRx's (NASDAQ:EQRX) Cash Burn Situation

Jul 24
Here's Why We're Not Too Worried About EQRx's (NASDAQ:EQRX) Cash Burn Situation

We Think EQRx (NASDAQ:EQRX) Can Afford To Drive Business Growth

Apr 08
We Think EQRx (NASDAQ:EQRX) Can Afford To Drive Business Growth

EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans

Dec 24
EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans

収支内訳

EQRx の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGM:EQRX 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Sep 230-260104204
30 Jun 230-263114240
31 Mar 230-272124244
31 Dec 220-169129227
30 Sep 220-146138211
30 Jun 220-100121179
31 Mar 220-53102153
31 Dec 210-10080116
30 Sep 210-27950229
30 Jun 210-29640256
31 Mar 210-26932237
31 Dec 200-25027223

質の高い収益: EQRX is currently unprofitable.

利益率の向上: EQRX is currently unprofitable.


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: EQRX is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.

成長の加速: Unable to compare EQRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

収益対業界: EQRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).


株主資本利益率

高いROE: EQRX has a negative Return on Equity (-22.23%), as it is currently unprofitable.


総資産利益率


使用総資本利益率


過去の好業績企業の発掘